UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000047567 |
|---|---|
| Receipt number | R000054243 |
| Scientific Title | National Cancer Center Hospital (NCCH) Phase1 Liquid Study |
| Date of disclosure of the study information | 2022/04/22 |
| Last modified on | 2025/04/24 09:18:53 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
National Cancer Center Hospital (NCCH) Phase1 Liquid Study
Acronym
NCCH Phase1 Liquid Study
Scientific Title
National Cancer Center Hospital (NCCH) Phase1 Liquid Study
Scientific Title:Acronym
NCCH Phase1 Liquid Study
Region
| Japan |
Condition
Condition
Cancer
Classification by specialty
| Hematology and clinical oncology |
Classification by malignancy
Malignancy
Genomic information
YES
Objectives
Narrative objectives1
Analysis of liquid samples and tissue samples in the patient with the advanced solid tumor who enrolled or will enroll in an early phase clinical trial.
Basic objectives2
Others
Basic objectives -Others
Analysis of clinical samples in a early phase clinical trial
Trial characteristics_1
Others
Trial characteristics_2
Others
Developmental phase
Not applicable
Assessment
Primary outcomes
Analysis of tumor and non-tumor tissue obtained based on the standardized operation procedure
Key secondary outcomes
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 18 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
Patient who pathologically diagnosed of cancer.
Patient who enrolled or will enroll in an early phase clinical trial.
Patient who has tissue sampling
Key exclusion criteria
No definition
Target sample size
160
Research contact person
Name of lead principal investigator
| 1st name | Toshio |
| Middle name | |
| Last name | Shimizu |
Organization
National Cancer Center Hospital
Division name
Department of Experimental Therapeutics
Zip code
104-0045
Address
5-1-1, Tsukiji, Chuo-ku, Tokyo
TEL
03-3542-2511
tosshimi@ncc.go.jp
Public contact
Name of contact person
| 1st name | Takafumi |
| Middle name | |
| Last name | Koyama |
Organization
National Cancer Center Hospital
Division name
Department of Experimental Therapeutics
Zip code
104-0045
Address
5-1-1 Tsukiji, Chuo-ku, Tokyo
TEL
03-3542-2511
Homepage URL
takoyama@ncc.go.jp
Sponsor or person
Institute
National Cancer Center Hospital
Institute
Department
Personal name
Funding Source
Organization
National Cancer Center Hospital
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
National Cancer Center IRB
Address
5-1-1 Tsukiji Chuo-ku Tokyo
Tel
03-3547-5201
irst@ml.res.ncc.go.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2022 | Year | 04 | Month | 22 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Enrolling by invitation
Date of protocol fixation
| 2020 | Year | 12 | Month | 15 | Day |
Date of IRB
| 2021 | Year | 01 | Month | 14 | Day |
Anticipated trial start date
| 2021 | Year | 01 | Month | 14 | Day |
Last follow-up date
| 2031 | Year | 03 | Month | 31 | Day |
Date of closure to data entry
| 2032 | Year | 03 | Month | 31 | Day |
Date trial data considered complete
| 2033 | Year | 03 | Month | 31 | Day |
Date analysis concluded
| 2034 | Year | 03 | Month | 31 | Day |
Other
Other related information
None
Management information
Registered date
| 2022 | Year | 04 | Month | 22 | Day |
Last modified on
| 2025 | Year | 04 | Month | 24 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000054243
